Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. develops noninvasive diagnostic tests for lung cancer and other lung diseases, with recurring news centered on its CyPath® Lung sputum-based diagnostic. Company updates describe clinical case studies, physician education, pulmonary nodule management, commercialization of the test, and laboratory services provided through Precision Pathology Laboratory Services.
News also covers bioAffinity’s flow cytometry and automated analysis platform, including research directed at asthma and chronic obstructive pulmonary disease diagnostics. The company reports developments involving clinical studies, scientific presentations, test adoption, revenue trends, equity financings, and the use of CyPath® Lung as a Laboratory Developed Test under CLIA oversight.
bioAffinity Technologies (NASDAQ: BIAF) closed a registered direct offering of 720,000 shares at $2.50 per share on Oct 9, 2025, raising approximately $1.8 million. WallachBeth Capital acted as sole placement agent. The company said it will use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares were offered under a shelf registration on Form S-3 (File No. 333-275608) declared effective Nov 27, 2023. A prospectus supplement describing the offering terms will be filed with the SEC and made available on the SEC website when available.
bioAffinity Technologies (NASDAQ: BIAF) announced on October 9, 2025 that it closed a registered direct offering of 720,000 common shares at $2.50 per share, raising approximately $1.8 million before offering expenses. WallachBeth Capital acted as sole placement agent. The company said net proceeds will be used for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares were offered under a Form S-3 shelf registration declared effective November 27, 2023, and a prospectus supplement describing the offering terms will be filed with the SEC.
bioAffinity Technologies (NASDAQ: BIAF, BIAFW) entered definitive agreements for a registered direct offering of 720,000 common shares at $2.50 per share, expected to close on or about October 9, 2025. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares are offered under an effective Form S-3 shelf registration (File No. 333-275608) and a prospectus supplement will be filed with the SEC.
bioAffinity Technologies (NASDAQ: BIAF) announced a registered direct offering of 720,000 shares of common stock at $2.50 per share, expected to close on or about October 9, 2025 subject to customary conditions. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales for CyPath® Lung, and for general corporate purposes. The shares are being offered under an effective Form S-3 shelf registration (File No. 333-275608); a prospectus supplement will be filed with the SEC.
bioAffinity Technologies (Nasdaq: BIAF) reported record CyPath® Lung test volumes in Q3 2025, with sales up 95% versus Q2 2025 and a 97% increase in sales for the first nine months of 2025 versus the same period in 2024. The company cited growing adoption by Veterans’ hospitals and expansion in the mid-Atlantic region.
Management highlighted a 77% increase in new patients using CyPath® Lung in Q3 and improved at-home sample collection compliance. Published case studies cited earlier detection (including Stage 1A) and fewer unnecessary invasive procedures.
bioAffinity Technologies (NASDAQ: BIAF) has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering consisted of 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 per pre-funded warrant).
WallachBeth Capital LLC served as the sole placement agent for the offering. The pre-funded warrants have an exercise price of $0.007 per share and will expire when exercised in full. The offering was conducted pursuant to an effective registration statement on Form S-1 filed with the SEC.
bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering included 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 for pre-funded warrants).
The pre-funded warrants have an exercise price of $0.007 per share and will expire upon full exercise. WallachBeth Capital, LLC served as the sole placement agent for this offering, which was conducted under an effective SEC registration statement on Form S-1.
["Raised $4.8 million in gross proceeds to strengthen balance sheet", "Successful completion of public offering indicates market interest"]bioAffinity Technologies (NASDAQ: BIAF, BIAFW), a biotechnology company developing early-stage cancer detection tests, has announced pricing for a $4.8 million public offering. The offering consists of 1,921,799 shares of common stock (or pre-funded warrants) priced at $2.50 per share (or $2.493 per pre-funded warrant).
The pre-funded warrants will have an exercise price of $0.007 per share and will be immediately exercisable until fully exercised. WallachBeth Capital LLC is serving as the sole placement agent, with the offering expected to close around September 30, 2025.
bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has announced pricing for a $4.8 million public offering. The offering consists of 1,921,799 shares of Common Stock (or pre-funded warrants) at $2.50 per share ($2.493 per pre-funded warrant).
The pre-funded warrants will have an exercise price of $0.007 per share and will be immediately exercisable until fully exercised. WallachBeth Capital, LLC is serving as the sole placement agent, with the offering expected to close around September 30, 2025.
bioAffinity Technologies (NASDAQ: BIAF) has released three new case studies demonstrating the clinical effectiveness of its CyPath® Lung noninvasive diagnostic test for lung cancer. The studies showcase how the test aids in critical clinical decision-making, with one case leading to early Stage 1A lung cancer detection and two cases helping avoid unnecessary invasive procedures.
The highlighted cases include: "Samuel," where a positive CyPath® Lung result convinced a hesitant patient to proceed with a biopsy, leading to early cancer detection; "David," where a negative result helped avoid an unnecessary biopsy; and "Lisa," where a positive result supported the decision to proceed with radiation treatment without a risky biopsy in a patient with end-stage COPD.